Skip to main content
Premium Trial:

Request an Annual Quote

Robert Hershberg

NanoString Technologies announced that Robert Hershberg has joined its board of directors as of March 2, bringing the total number of members to six.

Hershberg in July 2014 became VP of immuno-oncology at Celgene Corporation. He leads Celgene's early R&D efforts in that space and is in charge of the new Celgene Immuno-Oncology Center of Excellence in Seattle, Washington. Hershberg also founded and is CEO of VentiRx Pharmaceuticals and is an independent member of the board of directors for Adaptive Biotechnologies Corporation. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.